ARTESUNATE

Peak

artesunate

NDAINTRAVENOUSPOWDERPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Clinical Trials (5)

NCT06853184Phase 2Recruiting

Study Evaluating the Efficacy and Safety of Artesunate

Started Aug 2025
NCT06555809N/ARecruiting

Evaluation of Artesunate in Infants Being Treated for Severe Malaria

Started Oct 2024
NCT06165614Phase 1Completed

Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya

Started Mar 2024
17 enrolled
Cervix CancerCervix NeoplasmPrecancerous Conditions+1 more
NCT05140278Phase 2Completed

Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate

Started Jul 2022
NCT05285735N/ARecruiting

Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants

Started Jun 2022

Loss of Exclusivity

LOE Date
Feb 16, 2044
218 months away
Patent Expiry
Feb 16, 2044
Exclusivity Expiry
May 26, 2027

Patent Records (1)

Patent #ExpiryTypeUse Code
12121506
Feb 16, 2044
Product